论文部分内容阅读
目的:观察尿激酶(UK)静脉溶栓治疗急性心肌梗塞(AMI)的溶栓时机及临床疗效。方法:39例AMI患者,用UK静脉溶栓治疗,半小时内输注 100~150万单位。结果:①临床判断梗塞相关血管再通24例,再通率61.5%;2小时内、2~4小时、4~6小时及6~12小时内相关血管再通率分别为80.0%、72.7%、57.1%和44.4%;死亡4例,病死率10.3%;并发出血3例,出血率7.7%。②溶栓再通患者病死率(4.2%,1/24)明显低于未通患者(20.0%,3/15)。结论:UK溶栓治疗AMI安全有效。
Objective: To observe the timing and clinical effect of intravenous thrombolytic therapy of urokinase (UK) on acute myocardial infarction (AMI). Methods: Thirty-nine patients with AMI were treated with UK intravenous thrombolysis and infused 100 to 1.5 million units in half an hour. Results: ①24 cases of recanalization associated with infarction were clinically diagnosed, and the recanalization rate was 61.5%. The rates of recanalization within 2 hours, 2 to 4 hours, 4 to 6 hours and 6 to 12 hours were 80.0 %, 72.7%, 57.1% and 44.4% respectively; 4 died and the case fatality rate was 10.3%; 3 cases had concurrent bleeding and the bleeding rate was 7.7%. ② The mortality rate of patients receiving thrombolytic recanalization (4.2%, 1/24) was significantly lower than that of patients without recanalization (20.0%, 3/15). Conclusion: UK thrombolytic therapy for AMI is safe and effective.